HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Positive Results of Co-Administering Pfizer’s Prevnar 20 and COVID-19 Vaccine

Pfizer reports positive top-line results from a phase 3 study that simultaneously administered Prevnar 20 and its COVID-19 vaccine in older adults.

Pfizer announced positive top-line results from the phase 3 study, B7471026, suggesting the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) when administered simultaneously with the Pfizer-BioNTech COVID-19 vaccine.

In a statement, Kathrin U. Jansen, PhD, senior vice president and head of Vaccine Research & Development at Pfizer, said, “These new safety and immunogenicity data provide further evidence supporting the potential to administer PREVNAR 20 and the Pfizer-BioNTech COVID-19 Vaccine at the same time, thereby reducing the number of visits adults make to their doctor’s office or pharmacy for recommended immunization. As the COVID-19 vaccines and booster doses continue to be administered, we believe that healthcare providers have an opportunity to talk to their adult patients about other recommended vaccines in line with CDC guidance.”

Prevnar 20 is Pfizer’s pneumococcal conjugate vaccine. It includes capsular polysaccharide conjugates for serotypes that cause invasive pneumococcal disease (IPD), as well as high case-fatality rates, antibiotics resistance, and meningitis. Prevnar 20 offers the broadest conjugate serotype coverage and protects against more strains of pneumococcal pneumonia-causing bacteria than any other available vaccine.

In the study, Pfizer administered Prevnar 20 to 570 US adults aged 65 years and older. At the same time, the participants received either the Pfizer-BioNTech COVID-19 vaccine or placebo.

Prevnar 20 elicited similar responses for all 20 serotypes, whether participants received it alongside the COVID-19 vaccine (n=190) or with placebo (n=191). Additionally, responses to a booster dose of the Pfizer-BioNTech vaccine were similar when administered with Prevnar 20 or with placebo (n=189).

The safety profile of receiving both Prevnar 20 and a Pfizer-BioNTech vaccine booster reflected that of the Pfizer-BioNTech COVID-19 booster dose.

On June 8, 2021, the US Food and Drug Administration (FDA) approved Prevnar 20 for the prevention of invasive disease and pneumonia in adults 18 and older. It is currently indicated for the active immunization to prevent diseases caused by Streptococcus pneumoniae serotypes.